All Clinical Trials
Mater conducts clinical trials in a range of therapeutic areas including Cance, Nerouology, Medicine, Orthopaedics Surgery and Acute Care, and Mothers' and Babies Health. Clinical trials are an essential component of helathcare. They provide the evidence to evaluate the safety and efficacy of new treantments and diagnositics, and provide alternative treatment options for patients with unmet needs.
ABTECT-1: A potential new treatment for UC
The ABTECT-1 Study is being done to learn more about an investigational medication, called Obefazimod or 'ABX464', and its effect in people with ulcerative colitis (UC). UC causes inflammation in the lining of the colon (large intestine). The main symptoms of UC are pain and recurring diarrhoea, which may contain blood and/or mucus.
ACUMEN - Enhancing treatment outcomes after after gynaecological cancer through exercise
ADELE
The purpose of the study is to test whether the addition of an immunotherapy drug, called tislelizumab, to the standard of care treatment of high-risk endometrial cancer reduces the risk of the disease coming back, and to determine if the new course of therapy is well-tolerated by participants.
AMT-151-01
This study will investigate the use of a new medicine called AMT-151 which may be used in the future as a possible treatment for advanced solid tumours.
ANZadapt
The research study is testing a new way of taking hormone tablets for prostate cancer. The new method is called ‘adaptive therapy,’ also known as a pause/restart strategy.
ARORAGE-1001 - Inhalation Solution in Healthy Subjects and Patients With Inflammatory Lung Disease
ARO-RAGE is being developed as a potential asthma and CF treatment and is intended to reduce inflammation in the airways by blocking and inhibiting an important lung receptor (component) involved in the inflammatory response, known as RAGE (Receptor for Advanced Glycation End-products). By reducing inflammation and improving airflow, ARO-RAGE may be an effective treatment for asthma and CF.
ASCERTAIN - Do you have newly diagnosed prostate cancer?
An Open-label, Randomised, Phase I, Multi-centre Study to Investigate the Biological Effects of Saruparib (AZD5305) Alone, Darolutamide Alone, and in Combination Given Prior to Radical Prostatectomy in Men with Newly Diagnosed Prostate Cancer (ASCERTAIN)
Assessment of airway clearance techniques in adults with bronchiectasis
Feasibility of Electrical Impedance Tomography in assessing short-term effects of airway clearance techniques in adults with bronchiectasis, an observational study.
BGB-16673 - BTK-Degrader in combination for Relapsed or Refractory B-Cell Malignancies
CAMBRIA-2: Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next-Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine T
CAMBRIA-2: Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next-Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER /HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease